



CIF A-18.758.300
Avda de la Innovación, n 1
Edificio BIC (Ofic 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

Mercado Alternativo Bursátil
Plaza de la Lealtad, 1
28014 MADRID

Granada, 15 October 2015

RELEVANT FACT OF NEURON BIO, S.A.

Dear Sirs,

In compliance with the provisions of the MAB circular 9/2010 on information to be provided by the companies in expansion integrated in the MAB the company, Neuron Bio, S.A. (hereinafter “NEURON BIO” or the “Company”), hereby puts in knowledge the following information.

Neol Biosolutions S.A registered its capital increase with the Mercantile Register yesterday, on 14 October. The capital increase has a value of €1,549,900 through the issue and circulation of 861,000 shares, each at a price of €1.80; this means a nominal value of €0.48 plus a share premium of €1.32 per share.

The new shares are ordinary shares and belong to the same class and series as the shares currently in circulation and confer equal rights and obligations.

Press release is enclosed.

We remain at your disposal for any clarification you consider appropriate.

Kind regards,

Fernando Valdivieso Amate
Chairman of the Board of Directors



CIF A-18.758.300
Avda de la Innovación, n 1
Edificio BIC (Ofic 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

Press release

Neol Bio completes capital increase prior going public in the MAB

- **The capital increase, which has been directed to qualified investors, has been 100% completed**

Granada, 15 October 2015. Neol Bio, a subsidiary of Neuron Bio (NEU.MAB), has completed the capital increase amounting to €1.55 million authorized by its Board of Directors on 26 June. Subscription terms suppose a €16.6 million valuation of Neol Bio prior to its listing in the Spanish Alternative Stock Market (MAB). New shares shall be represented through book entries and shall have equal rights than those currently outstanding.

Neol Bio will go public in the MAB soon, once requirements of this market have been met. The 100% of Neol Bio shares will be traded on the Spanish Alternative Stock Market with no initial public offer. Neol Bio shares will be traded as "continuous auction".

Funds raised will be used to develop the Neol Bio Strategic Plan that was presented and unanimously adopted by the Extraordinary Shareholders' Meeting of Neuron Bio held the last 24 March. The major defined strategic goals of this Strategic Plan are:

-To position Neol Bio as a European reference biotechnology company for the production of high-added value oleochemicals from residue raw materials, focused on



CIF A-18.758.300
Avda de la Innovación, n 1
Edificio BIC (Ofic 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

the efforts of the platforms MicroBioOil 3.0® and Omega-3 DHA based on the acquired experience curve.

-To reach R&D service agreements in order to assess the platform Microbiotools®, mainly related to the extraction and production of oil and to the valorization of wastes.

Neol Bio is an industrial biotechnology company focused on the discovery and development of bioprocesses for the oleochemical, agrofood and biofuels sector.

Based on a property collection of over 9,000 microorganisms, NEOL BIO has experience, equipment and patented technologies for the selection and optimization of microorganisms from the phase of initial discovery to the pre-industrial phase. One of the company's differentiating factors is its expertise in assessment through biotechnological processes of agricultural and industrial waste.

For more information

Malena Valdivieso
mvaldivieso@neuronbio.com
Tel.: +34 958 750 598
www.neuronbio.com



CIF A-18.758.300
Avda de la Innovación, n 1
Edificio BIC (Ofic 211)
P. T. de Ciencias de la Salud
18100 Armilla (Granada)
Tel: 958 750 598

Note for editors

Neol Bio, a subsidiary of Neuron Bio is devoted to the development of innovative processes within the microbial industrial biotechnology for its application in oleochemical, bioenergy and biopolymer sectors.

Due to the use of advanced molecular biology techniques, bioprocess engineering and industrial microbiology, Neol achieves economically viable bioprocesses, thus reducing the use of chemical contaminants and assessing agricultural and industrial waste.

Neol has facilities, laboratories and cutting-edge equipment in the biotechnology field as well as an own pilot plant for demonstration of the processes it develops.

Neol has a team of over 30 high qualified researchers, such as microbiologists, molecular biologists, experts in analytical chemistry and bioprocesses engineers with renowned prestige in the sector, who participate actively in numerous scientific projects.

Its headquarters and main facilities are located in the Granada Bio Science & Technology Park.